S100B, human, 13C
- Known as:
- S100B, H. sapiens, 13C
- Catalog number:
- 201SB01_C
- Category:
- -
- Supplier:
- ProtEra
- Gene target:
- S100B human 13C
Related genes to: S100B, human, 13C
- Gene:
- S100B NIH gene
- Name:
- S100 calcium binding protein B
- Previous symbol:
- -
- Synonyms:
- S100beta
- Chromosome:
- 21q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-27
- Date modifiied:
- 2014-11-18
Related products to: S100B, human, 13C
Related articles to: S100B, human, 13C
- Early diagnosis of Parkinson's disease (PD) before extensive neurodegeneration is a critical unmet need, largely due to the absence of sensitive, minimally or non-invasive biomarkers for the prodromal stage. Here, we primarily use α-synuclein (α-Syn) preformed fibril (PFF)-induced mouse models to investigate the mechanistic basis of peripheral α-Syn dissemination, and additionally perform a small exploratory analysis of a serum-based α-Syn seed amplification assay (SAA) in a prodromal human cohort as proof-of-concept. In the PFF model, misfolded α-Syn propagated broadly throughout the CNS and the periphery well before motor symptom onset, with middle-aged mice exhibiting exacerbated pathology, reflecting age-related vulnerability. Proteomic profiling linked α-Syn-induced neurodegeneration to neuroinflammatory signaling, while microglia depletion significantly reduced both central α-Syn accumulation and peripheral spread, implicating activated microglia as key contributors to disease progression. As an exploratory translational step, we applied serum α-Syn SAA to a small cross-sectional cohort of isolated REM sleep behavior disorder (iRBD; n = 25) individuals and matched healthy controls (n = 25). Combining the blood-brain barrier (BBB) integrity marker S100B with SAA yielded 64% sensitivity and 100% specificity versus healthy controls. Collectively, our findings delineate a mechanistic framework linking microglia-driven neuroinflammation, BBB disruption, and peripheral α-Syn dissemination, and provide preliminary evidence that serum α-Syn SAA combined with BBB biomarkers is a mechanistically plausible candidate strategy for early PD detection. - Source: PubMed
Publication date: 2026/05/13
Kuang YaoyunMao HengxuLin HaoDai WeiSu ZhongqiangLuo YingZou Wen-QuanYang Xin-LingXu Ping-Yi - The objective of this secondary analysis was to examine the impact of two perfusion modalities on S100B levels and neural injury outcomes in congenital heart surgery patients undergoing cardiopulmonary bypass. - Source: PubMed
Publication date: 2026/05/11
Rajesh SrihariDayi KevsergülLussier Marc JMcKeone Daniel JHalstead E ScottKunselman Allen RMyers John LÜndar Akif - - Source: PubMed
- Dexmedetomidine (DEX) seems to hold a potential neuroprotective role, possibly mediated by the attenuation of oxidative stress and neuroinflammation. This study aimed to delineate the effect of DEX used as an adjunct anaesthetic on cerebral oxygenation, cerebral injury and the release of inflammatory markers in brain tumour surgery. - Source: PubMed
Publication date: 2026/05/08
Nikopoulou AnastasiaGrosomanidis VasileiosPoulopoulou AikaterinaVyzantiadis Timoleon-AchilleasPourzitaki ChryssaPatsalas IoannisTsaousi Georgia G - Acute ischemic stroke (AIS) remains a leading cause of disability worldwide, and effective treatments are urgently needed beyond reperfusion therapy. Translating preclinical success to clinical impact has been hindered by variability in animal models and the lack of translational biomarkers that predict outcomes across species. To overcome these barriers, we developed a robust rat AIS model optimized for consistency and severity, enabling rigorous therapeutic testing. Additionally, we tested a panel of common clinical serum biomarkers to improve translation from rodents to humans. We demonstrated that serum neurofilament light chain (NfL) -a biomarker widely used in clinical stroke studies- strongly correlated with functional outcomes, establishing a translational link that has not been previously reported in rats. Notably, NfL's predictive capabilities performed as well as infarct volume while outperforming serum biomarkers intercellular adhesion molecule-1 (ICAM-1) and S100 calcium binding protein (S100B). Using this platform, we evaluated the therapeutic impact of neural stem cell-derived extracellular vesicles (NSC EV), a novel biologic therapy poised for clinical trials, on stroke outcome in our rat AIS model. A three-dose regimen of NSC EV over 48 h confirmed our previous studies and produced the best outcomes in stroked animals evidenced by smaller infarct volume, improved neurologic score, and reduced serum NfL. In addition, single-dose and two-dose regimens of NSC EV were both effective at some endpoints. These findings not only validate NfL as a cross-species biomarker but also provide critical dosing insights for NSC EV therapy, accelerating the path from bench to bedside for AIS treatment. - Source: PubMed
Publication date: 2026/05/08
Cannon Megan KFojtik Alinde RWhite Charles MSwetenburg Raymond LStice Steven LSavitz Sean IBaker Emily W